Eton Pharmaceuticals Begins Clinical Trial for Extended-Release Wilson Disease Treatment — Eton Pharmaceuticals, Inc.

Event summary

Eton Pharmaceuticals dosed the first patient in a pilot clinical study for ET-700, an extended-release zinc acetate formulation for Wilson disease.
The double-blinded, placebo-controlled trial will enroll 36 healthy volunteers and use PET imaging to assess intestinal copper absorption.
Topline results are expected in the second half of 2026, with a potential pivotal study starting in early 2027 if data is positive.
Eton estimates ET-700 could achieve over $100 million in peak annual U.S. sales if approved.

The big picture

Eton Pharmaceuticals is targeting a significant unmet need in Wilson disease treatment with ET-700, aiming to improve patient compliance through extended-release formulation. The trial represents a strategic push into rare disease therapeutics, an area with high barriers to entry but substantial revenue potential for successful candidates. Success could position Eton as a key player in this niche market.

What we're watching

Clinical Efficacy: Whether ET-700 can demonstrate superior efficacy with a simpler dosing regimen compared to existing treatments.
Regulatory Pathway: The pace at which Eton advances from pilot to pivotal studies and potential FDA approval timelines.
Market Potential: How the $100 million peak sales estimate aligns with market realities for Wilson disease therapies.